InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (2 ops.)
Insider track record
CEODisclosed buys
1
Disclosed sells
2
T+90 hit rate
67%
T+90 mean return
+8.5%
Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by Orwin John A, Chairman & CEO. Officer active across 4 companies, notably Travere Therapeutics, Inc.. In total, 19 disclosures have been published. Breakdown: 1 buy · 2 sells. Total volume traded: €45k. Activity tracked since 14 May 2021. The latest transaction was filed on 15 June 2025 (Levée d'options). Regulator: SEC (Form 4). The full history is free.
Declarations19 total
6,030 shares0Common StockSEC:0001415889-25-017589:0
6,500 shares0Common StockSEC:0001415889-25-013501:0
1,300 shares0Common StockSEC:0001415889-24-023552:0
2,035 shares0Common StockSEC:0001415889-24-017508:0
6,500 shares0Common StockSEC:0001415889-24-012849:0
1 shares@ US$0.010.0% of flowSeries A Junior Preferred StockSEC:0001415889-24-011059:0
Ideal exit: 6 Jan 2025 (T+270)
22,951 shares@ US$0.374617.5% of flowClass A Common StockSEC:0001415889-24-010243:0
29,003 shares@ US$229.00100.0% of flowCommon StockSEC:0000950170-23-070863:0
2,044 shares0Common StockSEC:0001203311-23-000061:0
4,500 shares0Common StockSEC:0001209191-23-030956:0
20,908 shares@ US$1.775282.5% of flowClass A Common StockSEC:0001209191-22-050778:0
1,503 shares0Common StockSEC:0000899243-22-018465:0
3,000 shares0Common StockSEC:0001209191-22-028699:0
115,400 shares0Class A Common StockSEC:0001209191-21-055809
115,400 shares0Class A Common StockSEC:0001209191-21-055809:0
1,402 shares0Common StockSEC:0001203311-21-000032:0
3,000 shares0Common StockSEC:0001209191-21-033847
1,402 shares0Common StockSEC:0001203311-21-000032
3,000 shares0Common StockSEC:0001209191-21-033847:0
19 of 19 declarations
About Orwin John A
John A. Orwin is the President & CEO of Travere Therapeutics, Inc., Seagen Inc., and Atreca, Inc. He leads these companies with a strategic vision, overseeing operations and growth initiatives. John is responsible for implementing corporate strategies and managing stakeholder relationships. His experience in the biopharmaceutical sector is a valuable asset for the leadership of these organizations.
